Clinical Trials Directory

Trials / Sponsors / TransThera Sciences (Nanjing), Inc.

TransThera Sciences (Nanjing), Inc.

Industry · 17 registered clinical trials — 4 currently recruiting.

StatusTrialPhaseStarted
RecruitingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive a
Breast Cancer
Phase 22026-03-17
Not Yet RecruitingEfficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepa
Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
Phase 32026-01-01
RecruitingStudy of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Cholangiocarcinoma
Phase 32023-12-20
Active Not RecruitingStudy of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy an
Cholangiocarcinoma Metastatic
Phase 22023-11-17
RecruitingA Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
B-Cell Malignancies
Phase 12023-03-30
UnknownTT-00973-MS Tablets in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 12023-01-01
UnknownStudy to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
B-Cell Malignancies
Phase 12022-06-01
CompletedTo Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer
Phase 1 / Phase 22022-04-13
CompletedStudy to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation
Phase 22021-12-07
CompletedA Phase 1 Study of TT-00920 in Healthy Subjects
Healthy
Phase 12021-11-03
CompletedSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy
Healthy
Phase 12021-08-19
CompletedStudy of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Phase 12021-07-12
CompletedStudy of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer
Phase 1 / Phase 22021-03-14
CompletedRelative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulation
Healthy
Phase 12020-12-29
CompletedPhase I, First-In-Human Study of TT-00920 in Healthy Subjects
Healthy
Phase 12020-02-05
CompletedSafety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breas
Advanced Solid Tumors, Triple Negative Breast Cancer
Phase 12019-01-08
AvailableRollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
Advanced Solid Tumors, Cholangiocarcinoma
——